Mycophenolate Mofetil

According to the FDA label: Mycophenolate mofetil for oral suspension (MMF) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1) ], heart [see Clinical Studies (14.2) ] or liver transplants [see Clinical Studies (14.3) ] , in combination with other immunosuppressants.

100,444 adverse event reports submitted to the FDA (2001–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Mycophenolate Mofetil in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Mycophenolate Mofetil adverse event reports by reporter sex
SexReports
Male43,053
Female40,674
Unknown575

By Age Group

View age group data as a table
Mycophenolate Mofetil adverse event reports by reporter age group
Age groupReports
0-1710,693
18-3411,354
35-4917,225
50-6422,828
65-7410,031
75+2,579

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Mycophenolate Mofetil. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Mycophenolate Mofetil adverse event reports by reported outcome
OutcomeReports
Other Serious72,198
Hospitalization36,713
Death19,234
Life-Threatening10,229
Non-Serious6,299
Disability3,379

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Mycophenolate Mofetil. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Mycophenolate Mofetil adverse event reports by year
YearReports
20013
20032
2004264
2005313
2006587
2007750
20081,013
20091,547
20101,368
20111,578
20121,528
20131,510
20141,775
20152,127
20162,673
20174,367
20186,307
20198,428
20209,607
20219,141
20228,366
20239,700
202412,364
202512,343
2026 (partial)2,783

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Mycophenolate Mofetil

In FDA adverse event reports that mention Mycophenolate Mofetil, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026